Pharma outsourcing lowers costs but has significant downsides, according to the New England Journal of Medicine (and reported by the New York Times).

According to the NY Times, an article about the globalization of clinical trials published in The New England Journal of Medicine ”raises questions about the ethics and the science of increasingly conducting studies outside the United States — when the studies are meant to gather evidence for new drugs to gain approval in this country.”

Read the complete article here.

Related articles by Zemanta

• How to Lure Clinical Trials Back to the U.S. (blogs.wsj.com)